Drotaverinum

General characteristics. Structure:

Active ingredient: 0,02 g of Drotaverinum of a hydrochloride.

Excipients: sodium disulphite (sodium metasulphite), alcohol of ethyl 95%, sodium sulfite anhydrous, dinatrium эдетат a dihydrate, a benzetoniya chloride, citric acid monohydrate, sodium citrate pentasexivihydrat, water for injections.

Medicine with the expressed spasmolytic action.

Pharmacological properties:

Pharmacodynamics. Myotropic spasmolysant. Reduces receipt of calcium ions in smooth muscle cells (inhibits phosphodiesterase, leads to accumulation of intracellular tsAMF). Reduces a tone of unstriated muscles of internals and a peristaltics of intestines, expands blood vessels. Does not influence the autonomic nervous system, does not get into the central nervous system.

Existence of direct influence on smooth muscles allows to use as a spasmolysant in cases when drugs from the M-holinoblokatorov group are contraindicated (closed-angle glaucoma, a prostate hyperplasia). At parenteral administration effect of drug is shown in 2-4 min. The maximum effect occurs in 30 min.

Pharmacokinetics. It is evenly distributed on fabrics, gets into smooth muscle cells. Communication with proteins of a blood plasma - 95-98%. Elimination half-life 2-4 hours. It is generally removed by kidneys, to a lesser extent with bile. Does not get through a blood-brain barrier.

Indications to use:

Spasm of smooth muscles at a chronic gastroduodenit, chronic cholecystitis, a cholelithiasis, a postcholecystectomy syndrome, a peptic ulcer of a stomach and a 12-perstny gut, kardio-and a pylorospasm, a spastic colitis; a spasm of peripheral arterial vessels, brain vessels, renal colic, альгодисменорея, for weakening of reductions of a uterus and a spasmolysis of a neck of uterus at childbirth, when carrying out tool researches.

Route of administration and doses:

Intramusculary or subcutaneously, on 2-4 ml (40-80 mg) 1-3 times a day. Duration of treatment is 1-2 weeks. In need of long treatment pass to administration of drug inside.

In cases when the bystry effect is necessary, 2-4 ml (40-80 mg) of drug enter intravenously slowly into 10-20 ml 0,9% of solution of sodium of chloride or 5% of solution of a dextrose. To children up to 6 years appoint usually in a dose 10-20 mg 1-2 times a day, to children 6 years - in a dose of 20 mg 1-2 times a day are more senior.

Features of use:

It is necessary to avoid driving of the car and occupations other types of activity demanding high concentration of attention, speed of psychomotor reactions during 1 h after parenteral (especially intravenous) introduction.

Side effects:

Dizziness, heartbeat, lowering of arterial pressure, feeling of heat, perspiration, allergic skin reactions.

At intravenous administration - a collapse, an atrioventricular block, arrhythmias, oppression of a respiratory center.

At bystry intravenous administration nausea and vomiting can be noted.

Interaction with other medicines:

At simultaneous use can weaken protivoparkinsonichesky effect of a levodopa.

Strengthens action of a papaverine, Bendazolum and other spasmolysants (including M-holinoblokatorov), the lowering of arterial pressure caused by tricyclic antidepressants, quinidine and procaineamide.

Reduces spazmogenny activity of morphine.

Phenobarbital increases expressiveness of spasmolytic action of Drotaverinum of a hydrochloride.

Contraindications:

Individual intolerance, the expressed liver, renal, heart failure, atrioventricular block of the II-III degree, cardiogenic shock, arterial hypotension.

With care - the expressed atherosclerosis of coronary arteries, a prostate hyperplasia, glaucoma, the period of pregnancy and a lactation.

Overdose:

Symptoms. In high doses breaks atrioventricular conductivity, reduces excitability of a cardiac muscle, can cause a cardiac standstill and paralysis of a respiratory center.

Symptomatic treatment.

Storage conditions:

In the place protected from light at a temperature not above 25 °C. Not to freeze. In the place, unavailable to children, the Period of validity 2 years. Not to use after the expiry date specified on packaging

Issue conditions:

According to the recipe

Packaging:

Solution for injections of 20 mg/ml. On 2 ml in ampoules from light-protective glass. 5 ampoules in a blister strip packaging. 2 blister strip packagings together with the application instruction, a knife ampoule or the scarificator ampoule ceramic in a pack from a cardboard. On 10 ampoules together with the application instruction, a knife ampoule or the scarificator ampoule ceramic in a pack from a cardboard with partitions or lattices, or a separator from a cardboard for a retail container or paper bag. 10 ampoules with the application instruction, a knife ampoule or the scarificator ampoule ceramic in a box from a cardboard. When using ampoules with notches, rings or points the knife ampoule does not invest.